Skip to main content

Progressing a non-antibiotic antimicrobial treatment for Bovine Mastitis towards market - PanaMast


The world is facing an antibiotics crisis, with resistant bacteria rendering current treatments ineffective. Novel, effective solutions are urgently required for this $40bn global market. Westway Health (WWH) is based in Galway, Ireland, and is on track to become a leading veterinary antimicrobials company in the EU. It has developed an innovative, non-antibiotic technology, effective at killing all bacteria, including antibiotic-resistant bacteria like MRSA, while not inducing resistance. WWH’s lead product in development is PanaMastTM LC, a breakthrough treatment of bovine mastitis, the most economically important infectious disease affecting the dairy industry. PanaMastTM LC will represent a step change in the way that dairy farmers manage mastitis, which affects 30% of the herd annually. It will: 1. Be the world’s first non-antibiotic medicine for mastitis, offering superior clinical outcomes and significant financial gains to end-users (€150/case); 2. Reduce wastage of milk and culling of cows; (3) Improve profitability and environmental performance on European farms and dairy processing sites. The innovation directly addresses the major global problem of antibiotic resistance, while providing a sustainable animal health solution that supports production of safe and high quality food. The Phase 1 PanaMast project was successfully completed ahead of schedule and on budget. It allowed WWH to: 1. Develop a regulatory roadmap detailing all steps required to progress from current stage of development (TRL7) to first sale of commercial product (TRL8); 2. Develop a robust commercial exploitation plan for PanaMastTM LC in EU and global markets; 3. Establish key strategic relationships to assist commercialisation of PanaMastTM LC
The Phase 1 results underpin this proposed project. The Phase 2 activities (pre-commercialisation/product development/product launch and commercialisation) are designed to ensure market launch and sale of PanaMastTM LC in the EU at TRL8 by 2020

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /agricultural sciences/animal and dairy science/dairy
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance/antibiotic resistance

Call for proposal

See other projects for this call

Funding Scheme

SME-2 - SME instrument phase 2


Unit 204 Business Innovation Centre Nuig Newcastle
H91 Galway
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 2 484 466,43